Tech Company Financing Transactions
Argos Therapeutics Funding Round
Argos Therapeutics closed a $17.5 million Series E funding round on 11/21/2013. Backers included private investors.
Transaction Overview
Company Name
Announced On
11/21/2013
Transaction Type
Venture Equity
Amount
$17,500,000
Round
Series E
Investors
Proceeds Purpose
This funding further strengthens our ability to advance our ADAPT clinical trial. In addition, the company is now better positioned to consider and pursue a range of options to support our global manufacturing and commercialization plans based on the potential of our Arcelis technology platform.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
4233 Technology Dr.
Durham, NC 27704
USA
Durham, NC 27704
USA
Phone
Website
Email Address
Overview
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis technology platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Abbey
Chief Financial Officer
Richard Katz
Chief Scientific Officer
Charles Nicolette
VP - Finance
Lori Harrelson
Browse more venture capital transactions:
Prev: 11/21/2013: ALOHA venture capital transaction
Next: 11/21/2013: Apartment List venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs